Bacil Pharma Ltd () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.04 k (-51.46%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.08%

how big is Bacil Pharma?

07-May-2025

As of May 05, Bacil Pharma Ltd has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company, with net sales of 0.00 Cr and a net profit of 0.35 Cr over the latest four quarters. Shareholder's funds are reported at 1.21 Cr, and total assets amount to 1.27 Cr as of the latest annual period ending in Mar'24.

When is the next results date for Bacil Pharma?

27-May-2025

No Upcoming Board Meetings

Is Bacil Pharma overvalued or undervalued?

09-Jun-2025

As of November 17, 2023, Bacil Pharma is considered risky and overvalued with a PE ratio of 24.47 and a troubling ROCE of -13.29%, despite a strong one-year stock return of 70.54%, contrasting with a year-to-date decline of 27.35%.

What is the technical trend for Bacil Pharma?

09-Jun-2025

As of May 26, 2025, Bacil Pharma shows a mildly bullish trend due to daily moving averages and monthly MACD signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution.

How has been the historical performance of Bacil Pharma?

15-Nov-2025

Bacil Pharma has not generated revenue from March 2019 to March 2025 but improved its financial position by reducing total expenditure and achieving a profit after tax of 0.40 crore in March 2025, recovering from previous losses. Additionally, total assets increased significantly from 1.27 crore in March 2024 to 25.55 crore in March 2025, indicating better asset management.

Why is Bacil Pharma falling/rising?

04-Dec-2025

As of 04-Dec, Bacil Pharma Ltd's stock price is rising to 41.12, reflecting a 0.44% increase. This growth is driven by strong recent performance, increased investor interest, and positive technical indicators, outperforming the benchmark Sensex significantly.

Which are the latest news on Bacil Pharma?

05-Dec-2025

How has been the historical performance of Bacil Pharma?
How has been the historical performance of Bacil Pharma?

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 60 Cr (Small Cap)

P/E

50.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.11

Return on Equity

4.64%

Price to Book

2.32

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

0 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

-25.19%

2 Years

663.65%

3 Years

459.32%

4 Years

947.85%

5 Years

639.11%

Bacil Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

How has been the historical performance of Bacil Pharma?

Answer: The historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. Breakdown: Bacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consist...

How has been the historical performance of Bacil Pharma?

Answer: The historical performance of Bacil Pharma shows a consistent trend of zero net sales and other operating income from March 2019 to March 2025. The total operating income remained at zero throughout this period, with the only notable expense being employee costs, which increased slightly from 0.05 crore in March 2021 to 0.14 crore in March 2025. The total expenditure, excluding depreciation, peaked at 3.92 crore in March 2022 but has since decreased to 0.25 crore by March 2025. Operating profit (PBDIT) was negative across all years, with a significant loss of 3.92 crore in March 2022, improving to a positive 0.41 crore in March 2025. Profit after tax also turned positive in March 2025 at 0.40 crore, a significant recovery from losses in previous years. The company's total assets increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily due to a rise in non-current ...

Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

01-Dec-2025 | Source : BSE

Resignation of Wholetime Company Secretary

Un-Audited Financial Result For 30Th September 2025

13-Nov-2025 | Source : BSE

Un Audited Financial Result for 30th September 2025

Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2025

13-Nov-2025 | Source : BSE

Outcome of Board Meeting Held on 13th November 2025

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

1.55%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

-92.84%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.34

EV to EBIT

-56.71

EV to EBITDA

-56.71

EV to Capital Employed

2.49

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1.06%

ROE (Latest)

4.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Sub Total A2 (0.08%)

Highest Public shareholder

Nikita Hiren Patel (19.44%)

Individual Investors Holdings

80.95%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -97.92% vs 4,900.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.04",
          "val2": "-0.07",
          "chgp": "42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.01",
          "val2": "0.48",
          "chgp": "-97.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is 4,400.00% vs -50.00% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.12",
          "val2": "-0.07",
          "chgp": "-71.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.45",
          "val2": "0.01",
          "chgp": "4,400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 4,000.00% vs 50.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.18",
          "val2": "-0.13",
          "chgp": "-38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.39",
          "val2": "-0.01",
          "chgp": "4,000.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 766.67% vs 40.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.25",
          "val2": "-0.19",
          "chgp": "-31.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.40",
          "val2": "-0.06",
          "chgp": "766.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.04

-0.07

42.86%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

0.01

0.48

-97.92%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Standalone Net Profit

YoY Growth in quarter ended Sep 2025 is -97.92% vs 4,900.00% in Sep 2024

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'24

Sep'24

Sep'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.12

-0.07

-71.43%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

0.45

0.01

4,400.00%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Standalone Net Profit

Growth in half year ended Sep 2024 is 4,400.00% vs -50.00% in Sep 2023

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.18

-0.13

-38.46%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

0.39

-0.01

4,000.00%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is 4,000.00% vs 50.00% in Dec 2023

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.25

-0.19

-31.58%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

0.40

-0.06

766.67%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Standalone Net Profit

YoY Growth in year ended Mar 2025 is 766.67% vs 40.00% in Mar 2024

All Annual Results

Company CV

About Bacil Pharma Ltd

Bacil Pharma Ltd

Small Cap

Pharmaceuticals & Biotechnology

Incorporated as a private limited company in Maharashtra in May '87, Bacil Pharma (BPL) was converted into a public limited company in Oct.'90. The main business activity of the Company is Pharmaceutical. Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India.

Company Coordinates

Company Details

71 Laxmi Building, Sir P M Road Fort Mumbai Maharashtra : 400001

Tel: 91-022-22618452

http://www.bacilpharma.com

bacilpha@yahoo.com

Registrar Details

Bigshare Services Pvt Ltd , E-2 , Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Andheri (E), Mumbai

Bacil Pharma

1Day

52 Week

CASH

FII

DII

Promoter

how big is Bacil Pharma?

Watch in Real-Time

When is the next results date for Bacil Pharma?

Is Bacil Pharma overvalued or undervalued?

What is the technical trend for Bacil Pharma?

How has been the historical performance of Bacil Pharma?

Why is Bacil Pharma falling/rising?

Which are the latest news on Bacil Pharma?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

How has been the historical performance of Bacil Pharma?

How has been the historical performance of Bacil Pharma?

Announcements

Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

Un-Audited Financial Result For 30Th September 2025

Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2025

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Standalone) - Sep'25 - YoY

Half Yearly Results Snapshot (Standalone) - Sep'24

Nine Monthly Results Snapshot (Standalone) - Dec'24

Annual Results Snapshot (Standalone) - Mar'25

About Bacil Pharma Ltd

Company Coordinates